Acamprosate's chemical structure
Find information on thousands of medical conditions and prescription drugs.

Acamprosate

Acamprosate, also known by the brand name Campral, is a drug used for treating alcohol dependence. It balances chemicals in your brain that are otherwise unbalanced due to alcoholism. Reports indicate that Acamprosate only works with a combination of attending support groups and abstinence from alcohol. Certain serious side effects include allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. more...

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

While the FDA in the United States approved this drug in July 2004, this drug has been legal in Europe since 1989. Upon the FDA's approval, they have released this statement:

"While its mechanism of action is not fully understood, Campral is thought to act on the brain pathways related to alcohol abuse. Campral was demonstrated to be safe and effective by multiple placebo-controlled clinical studies involving alcohol-dependent patients who had already been withdrawn from alcohol, (i.e., detoxified). Campral proved superior to placebo in maintaining abstinence (keeping patients off alcohol consumption), as indicated by a greater percentage of acamprosate-treated subjects being assessed as continuously abstinent throughout treatment. Campral is not addicting and was generally well-tolerated in clinical trials. The most common adverse events reported for patients taking Campral included headache, diarrhea, flatulence, and nausea."

The brand of this drug, Campral, is manufactured by Merch-Lipha in France. They are sold as 333mg white and odorless tablets of Acamprosate calcium, which is the equivalent of 300mg of Acamprosate.

Read more at Wikipedia.org


[List your site here Free!]


Acamprosate in the treatment of alcohol dependency - adapted from the Lancet 1996;347;1438-42 - Tips from Other Journals
From American Family Physician, 9/1/96

Approximately one-half of alcoholic patients relapse within three months of completing treatment. Several neurochemical agents may influence the mechanism of alcoholic cravings and relapse. Although the mechanisms are unknown, some studies have reported promising results with drugs that influence transmission of serotonin, dopamine and gamma-aminobutyric acid. Whilworth and colleagues conducted a double-blind, placebo-controlled study to assess the efficacy and safety of longterm use of acamprosate (calcium acetylhomotaurinate) in the treatment of alcohol dependency.

Patients treated by five Austrian hospitals for chronic or episodic alcoholism of at least 12 months' duration were eligible for the study. Alcoholism was validated by the CAGE questionnaire, the Michigan alcoholism screening test, and elevated liver function values and mean corpuscular volume. Patients with severe coexistent disease were excluded from the study. A total of 455 patients who had completed five days of alcohol withdrawal treatment were randomly assigned to receive either acamprosate or placebo. Patients were assessed on day 0 and on days 30, 90, 180, 270 and 360 for evidence of relapse and occurrence of side effects. The duration of treatment was 360 days. Patients were reassessed at 450, 540, 630 and 720 days. Seven patients recruited for the study did not receive medication and were therefore not included. Of the 448 remaining patients, 179 patients completed 12 months of treatment and 148 patients were followed for an additional year after the trial.

The placebo and treatment groups did not differ significantly in measures of severity of alcoholism and depression, or in demographic variables. By 360 days, 41 (18.3 percent) of the acamprosate-treated patients and 16 (7.1 percent) of placebo-treated patients had been continuously abstinent. The numbers and reasons for withdrawal from the trial were similar in both groups of patients. Relapse was the most common reason for withdrawal, and one-half of the relapses occurred within the first 90 days of treatment. The time to treatment failure continued to show a significant difference in favor of acamprosate. By the end of the two-year study, 27 patients (11.9 percent) in the acamprosate-treated group and 11 patients (4.9 percent) in the placebo-treated group remained continuously abstinent. No significant differences in side effects, with the exception of diarrhea, were detected between the two patient groups. Diarrhea was reported by 20.1 percent of patients taking acamprosate, compared with 12.1 percent of the placebo group.

The authors conclude that although treatment of alcoholism is notoriously difficult, acamprosate can be a safe and effective adjunct to rehabilitation programs. The authors believe that treatment should include a psychosocial element as well as a pharmacologic approach. The development of such treatments has the potential to benefit patients, reduce health care costs and alleviate the enormous social costs of alcoholism. (Whitworth AB, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-42.)

COPYRIGHT 1996 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group

Return to Acamprosate
Home Contact Resources Exchange Links ebay